CSL spends $117M to support development of VarmX’s blood clotting drug

CSL and VarmX have inked a $117 million deal focused on advancing the Dutch biotech’s blood coagulation candidate’s Phase 3 development. And if that trial yields positive results, the Australian drugmaker could end up buying ...